| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 776,133 | 825,410 | 745,145 | 745,740 |
| Cost of sales | 140,085 | 150,090 | 151,558 | 188,457 |
| Research and development | 409,478 | 161,308 | 158,731 | 184,901 |
| Selling, general and administrative | 268,415 | 232,279 | 206,116 | 253,480 |
| Intangible asset amortization | 4,847 | 4,846 | 4,847 | 5,009 |
| Gain on sale of nonfinancial assets | 0 | 0 | 0 | 0 |
| Total operating expenses | 822,825 | 548,523 | 521,252 | 631,847 |
| Income (loss) from operations | -46,692 | 276,887 | 223,893 | 113,893 |
| Interest income | 17,854 | 18,827 | 19,013 | 18,053 |
| Interest expense | 2,579 | 2,679 | 2,863 | 2,968 |
| Other income, net | 5,093 | 4,833 | -1,954 | 5,463 |
| Income (loss) before income taxes | -26,324 | 297,868 | 238,089 | 134,441 |
| Provision for income taxes | 4,420 | 57,336 | 52,403 | 28,361 |
| Net income (loss) | -30,744 | 240,532 | 185,686 | 106,080 |
| Earnings (loss) per share, basic (in dollars per share) | -0.16 | 1.25 | 0.97 | 0.56 |
| Earnings (loss) per share, diluted (in dollars per share) | -0.16 | 1.23 | 0.95 | 0.55 |
| Weighted average common shares outstanding, basic (in shares) | 192,032,000 | 191,907,000 | 190,967,000 | 190,429,000 |
| Weighted average common shares outstanding, diluted (in shares) | 192,032,000 | 197,091,000 | 196,474,000 | 197,147,000 |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)